Quality of life (QOL) for the treatment sequence of abiraterone acetate plus prednisone (AAP) followed by enzalutamide (ENZ) versus the opposite sequence for metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized clinical trial.

Daniel Khalaf,Katherine Sunderland,Bernhard J. Eigl,Daygen L. Finch,Conrad D. Oja,Joanna Vergidis,Muhammad Zulfiqar,Christian K. Kollmannsberger,Martin E. Gleave,Kim N. Chi

Quality of life (QOL) for the treatment sequence of abiraterone acetate plus prednisone (AAP) followed by enzalutamide (ENZ) versus the opposite sequence for metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized clinical trial.

2020

Daniel Khalaf
Katherine Sunderland
Bernhard J. Eigl
Daygen L. Finch
Conrad D. Oja
Joanna Vergidis
Muhammad Zulfiqar
Christian K. Kollmannsberger
Martin E. Gleave
Kim N. Chi

5578Background: A randomized cross-over phase II trial (Lancet Oncol 20(12):1730, 2019) showed the sequence of AAP followed by ENZ is associated with a better time to PSA progression compared with ...

Keywords:

Enzalutamide
Oncology
Abiraterone acetate
treatment sequence
Internal medicine
Quality of life
castration resistant
Pathology
Prostate cancer
Randomized controlled trial
Prednisone
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations